Pomalyst, Darzalex, and Corticosteroids

Weekly Infusion Number 6:  Blood draw, doctor visit, pre-medications, and Darzalex, about 6 hours total. I took 20 mg dexamethasone last night, as part of the Pomalyst regimen, and received 100 mg of prednisone IV before the Darzalex, as part of that regimen. As before no problems, no infusion reactions.  This is getting boring. Boring is good.  I love boring.
Source: Myeloma Hope - Category: Cancer & Oncology Tags: corticosteroids daratumumab Darzalex dexamethasone pomalidomide Pomalyst prednisone Source Type: blogs

Related Links:

Multiple myeloma (MM) is a malignancy of plasma cells that primarily reside in the bone marrow and in most cases involves the secretion of monoclonal paraproteins. Treatments for MM include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors, and immunomodulatory agents [1]. High-dose chemotherapy (HDC) in combination with autologous hematopoietic stem cell transplantation (auto-HSCT) has improved clinical responses [2-7] and the success of this treatment is partly due to the efficacy of pre-transplant HDC regimens.
Source: Experimental Hematology - Category: Hematology Authors: Source Type: research
AbstractPolyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome is a rare cause of demyelinating polyneuropathy associated with monoclonal proliferation of plasma cells. Because the disorder shows diverse symptoms, its diagnosis is often difficult. Previously reported diagnostic criteria had many items and their accuracy was not confirmed. Recently new diagnostic criteria are proposed, which consist of only seven items and have better diagnostic accuracy.Since around 2000, treatments for myeloma, such as high ‚Äźdose chemotherapy with autologous stem cell transplantation, immu...
Source: Clinical and Experimental Neuroimmunology - Category: Neurology Authors: Tags: REVIEW ARTICLE (INVITED) Source Type: research
Abstract Nowadays, bortezomib, a proteasome inhibitor, is widely used in treatment of newly diagnosed or relapsed multiple myeloma. The aim of this study was to analyze efficiency of bortezomib retreatment in patients with relapsed or refractory multiple myeloma. From 2004 to 2016, 283 patients were retrospectively evaluated at all hematological centers in the Czech Republic. Bortezomib was administered at the standard dosing and in combined therapy with corticosteroids, chemotherapy or thalidomide. Before bortezomib retreatment, 61% of patients received previous lenalidomide treatment, 40.6% autologous transplant...
Source: Neoplasma - Category: Cancer & Oncology Authors: Tags: Neoplasma Source Type: research
Diffuse alveolar hemorrhage (DAH) may occur with vasculitis, infection, and coagulation disorders. In patients with hematologic malignancies such as leukemia, lymphoma and multiple myeloma, the risk of death from DAH is 70%. Although their effectiveness remains uncertain, corticosteroids are the mainstay of treatment. It is not easy to determine the use of corticosteroids because of the adverse effects such as worsening of infections, gastrointestinal (GI) bleeding and poor blood glucose control. Retrospective analysis was performed at a single medical center in South Korea from August 2005 to April 2018. DAH was diagnosed...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Rare ILD/DPLD Source Type: research
The diagnosis of primary systemic amyloidosis, also known as AL (amyloid light-chain) amyloidosis, is often delayed owing to its nonspecific manifestations as well as its rarity. A 64-year-old woman presented with an eight-month history of significant weight loss, anemia, fatigue, and progressive painful cutaneous lesions on her hands, lips, back, perianal, and vulvar area that were originally treated unsuccessfully with antimalarials and systemic corticosteroids. Histopathological examination revealed an amorphous dermis with pale pink material that demonstrated positive birefringence with Congo red staining. Subsequently...
Source: Dermatology Online Journal - Category: Dermatology Source Type: research
Pomalidomide (pom), an immunomodulatory agent, in combination with low-dose dexamethasone (dex), is approved for the treatment of multiple myeloma (MM) refractory to lenalidomide (R) and bortezomib (V). Herein we report on the efficacy and safety of pom with/without dex in the real world setting.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Corticosteroids (steroids) play a central role in the treatment of MM and are widely recognised to cause a wide range of side effects that adversely impact health related quality of life (HRQoL). Patient reported outcome measures (PROMs) are tools that enable patients to report their health status and the presence and severity of symptoms. A range of PROMs are available to assess symptoms in MM but no such tool exists to measure the impact of steroids in this population. The Dexamethasone Symptom Questionnaire Chronic (DSQ-C) is an 18-item measure, initially developed to determine the incidence and severity of symptoms exp...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Corticosteroids remain the backbone of treatment for myeloma, recognised to cause a wide range of side effects. To date, as no instrument exists, the frequency and severity of these side effects are not reported as part of the routine care. The Dexamethasone Symptom Questionnaire Chronic (DSQ-Chronic) was designed to report side effects associated to dexamethasone given as an anti-emetic in cancer patients. We adapted the DSQ-C to reflect the higher doses and duration of treatment in a Multiple Myeloma (MM) population.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
POEMS syndrome is a rare paraneoplastic syndrome caused by an underlying plasma cell disorder. The combination of a proteasome inhibitor, an IMiD and corticosteroid is known to be highly effective among patients with myeloma.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Authors: Ghermezi M, Spektor TM, Berenson JR Abstract Multiple myeloma (MM) is the most common primary malignancy of the bone marrow. No established curative treatment is currently available for patients diagnosed with MM. In recent years, new and more effective drugs have become available for the treatment of MM. Many newer drugs have been evaluated together and in combination with older agents. However, even in combination with other active MM agents, the responses are transient, and; thus, therapeutic approaches to help overcome resistance to these drugs are necessary. Recently, the Janus kinase (JAK) family of ...
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
More News: Corticosteroid Therapy | Dexamethasone | Myeloma | Prednisone